The mechanism which underlies the susceptibility of liver disease patients to life-threatening infection has been uncovered by Wellcome Trust-funded medical scientists, who have also suggested a possible treatment to reverse immune suppression in these patients.
Liver disease, or cirrhosis, is currently the fifth leading cause of death in the UK. Cirrhosis patients are more than five times more likely to pick up infections in hospital than patients with other chronic conditions, due to reduced immunity which is a well-recognised feature of the disease.
In a study published today in Nature Medicine, researchers at UCL propose that the underlying cause of hyper susceptibility to infection in cirrhosis patients is due to the over production of the lipid hormone prostaglandin E2 (PGE2). This hormone prevents white blood cells from ingesting bacteria and killing them.
In the study, 75 blood samples were taken from patients at hospitals including University College Hospital, Royal Free Hospital, Royal London Hospital, St Mary's Hospital and the Hospital Clinic of Barcelona.
Researchers also found that a decreased concentration globular blood protein albumin, which catalyses the inactivation of PGE2 in liver disease patients was contributing to low immunity.
The authors of the study have therefore suggested that cirrhosis patients should receive albumin infusions to reverse immune suppression in chronic liver disease.
The research was carried out by lead author Professor Derek Gilroy, Wellcome Trust Senior Research Fellow at UCL in collaboration with consultant hepatologist Dr Alistair O'Brien.
Professor Gilory said: "A defective innate immune response was first observed in cirrhosis 30 years ago, and infection is most common cause of death in cirrhosis patients. However, the precise factors that cause reduced immunity have up until now been unknown.
"Our research has uncovered a powerful mechanism for immune suppression in cirrhosis patients and also proposes a relatively simple and safe treatment."
Dr O'Brien added: "We have discovered that the immune system of patients with advanced liver disease can be boosted for at least 24 hours by infusing albumin into a vein which reduces PGE2's effects. This safe process is currently given when patients need extra fluid, for example those with kidney damage.
"We propose that albumin be given daily to improve cirrhosis patients' immune systems and therefore prevent infection. We hope that this will save lives and reduce health-care costs and we intend to investigate this in a large scale clinical trial."
The researchers plan to carry out a clinical trial looking at the ability of albumin to reverse immune suppression in liver cirrhosis starting this summer. The trial is supported by the Wellcome Trust.
Senior Media Officer
The Wellcome Trust
T: +44 (0)20 7611 7262
Notes for editors
About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. http://www.wellcome.ac.uk
Clare Ryan | Eurek Alert!
Fast-tracking T cell therapies with immune-mimicking biomaterials
16.01.2018 | Wyss Institute for Biologically Inspired Engineering at Harvard
Dengue takes low and slow approach to replication
12.01.2018 | Duke University
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
16.01.2018 | Materials Sciences
16.01.2018 | Materials Sciences
16.01.2018 | Power and Electrical Engineering